[go: up one dir, main page]

ATE437873T1 - 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten - Google Patents

4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Info

Publication number
ATE437873T1
ATE437873T1 AT06850430T AT06850430T ATE437873T1 AT E437873 T1 ATE437873 T1 AT E437873T1 AT 06850430 T AT06850430 T AT 06850430T AT 06850430 T AT06850430 T AT 06850430T AT E437873 T1 ATE437873 T1 AT E437873T1
Authority
AT
Austria
Prior art keywords
ylü
benzoäbüthiophen
pyrimidine
cancer
treatment
Prior art date
Application number
AT06850430T
Other languages
English (en)
Inventor
Karl Dahnke
Ho-Shen Lin
Chuan Shih
Q Wang
Bo Zhang
Michael Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE437873T1 publication Critical patent/ATE437873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06850430T 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten ATE437873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
ATE437873T1 true ATE437873T1 (de) 2009-08-15

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850430T ATE437873T1 (de) 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Country Status (27)

Country Link
US (1) US7547691B2 (de)
EP (1) EP1989200B1 (de)
JP (1) JP2009516697A (de)
KR (1) KR100990771B1 (de)
CN (1) CN101309918B (de)
AR (1) AR057911A1 (de)
AT (1) ATE437873T1 (de)
AU (1) AU2006337626B2 (de)
BR (1) BRPI0618245A2 (de)
CA (1) CA2629336A1 (de)
CR (1) CR9947A (de)
DE (1) DE602006008187D1 (de)
DK (1) DK1989200T3 (de)
EA (1) EA014426B1 (de)
EC (1) ECSP088456A (de)
ES (1) ES2329085T3 (de)
IL (1) IL190489A0 (de)
MA (1) MA30053B1 (de)
NO (1) NO20082594L (de)
PE (1) PE20070833A1 (de)
PL (1) PL1989200T3 (de)
PT (1) PT1989200E (de)
SI (1) SI1989200T1 (de)
TN (1) TNSN08227A1 (de)
TW (1) TW200800201A (de)
WO (1) WO2007092095A2 (de)
ZA (1) ZA200803940B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01143B (me) 2006-03-31 2013-03-20 Janssen Pharmaceutica Nv BENZOIMIDAZOL-2-IL PIRIMIDINI l PIRAZINI KAO MODULATORI HISTAMINSKOG H4 RECEPTORA
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
US8063212B2 (en) * 2006-12-21 2011-11-22 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
CN101563342B (zh) * 2006-12-21 2012-09-05 伊莱利利公司 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物
PE20090803A1 (es) 2007-05-16 2009-07-11 Lilly Co Eli Compuestos triazolil aminopirimidin como inhibidores de plk1
MX2009012228A (es) 2007-05-16 2009-12-01 Lilly Co Eli Compuesto de triazolil aminopirimidina.
MX2011000080A (es) 2008-06-30 2011-03-02 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de pirimidina sustituidos.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
MX2012012502A (es) 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CA2864085C (en) 2012-02-08 2021-11-23 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法

Also Published As

Publication number Publication date
IL190489A0 (en) 2008-11-03
ZA200803940B (en) 2009-09-30
JP2009516697A (ja) 2009-04-23
NO20082594L (no) 2008-06-10
TNSN08227A1 (en) 2009-10-30
CN101309918A (zh) 2008-11-19
AR057911A1 (es) 2007-12-26
DE602006008187D1 (de) 2009-09-10
EA014426B1 (ru) 2010-12-30
US7547691B2 (en) 2009-06-16
ES2329085T3 (es) 2009-11-20
KR20080059451A (ko) 2008-06-27
PT1989200E (pt) 2009-10-12
BRPI0618245A2 (pt) 2011-08-23
DK1989200T3 (da) 2009-11-09
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626A8 (en) 2008-06-19
MA30053B1 (fr) 2008-12-01
WO2007092095A3 (en) 2007-11-08
CR9947A (es) 2008-11-28
EP1989200A2 (de) 2008-11-12
TW200800201A (en) 2008-01-01
AU2006337626B2 (en) 2012-03-22
EP1989200B1 (de) 2009-07-29
WO2007092095A2 (en) 2007-08-16
EA200801362A1 (ru) 2009-02-27
KR100990771B1 (ko) 2010-10-29
US20080306082A1 (en) 2008-12-11
ECSP088456A (es) 2008-06-30
PE20070833A1 (es) 2007-08-27
CN101309918B (zh) 2010-12-29
PL1989200T3 (pl) 2009-12-31
SI1989200T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
ATE437873T1 (de) 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1898930A4 (de) Behandlung von entzündlichen erkrankungen
EP1954274A4 (de) Substituierte chinolone und verwendungsverfahren
SE531352C8 (sv) Spiroalkanderivat och användning av dessa föreningar för behandling av artrit, cancer, kardiovaskulära sjukdomar, hudsjukdomar och inflammatoriska och allergiska tillstånd
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
EP2182983A4 (de) Behandlung von amyloidogenen erkrankungen
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
DE602005007623D1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EP2173740A4 (de) Häm-oxygenase-inhibitoren und deren verwendung bei der behandlung von krebs und krankheiten des zentralen nervensystems
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20081539L (no) Middel for behandling av betennelsestarmsykdom
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
DE602005020263D1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1989200

Country of ref document: EP